Literature DB >> 11508831

Suppression of polyclonal immunoglobulin production by M-proteins shows isotype specificity.

L Wang1, D C Young.   

Abstract

Monoclonal gammopathies are B cell neoplasms that are characterized by the presence of monoclonal immunoglobulins (M-proteins) in the serum. By an unknown mechanism, the normal polyclonal immunoglobulin levels are frequently reduced in sera of these patients. To assess the role of M-protein isotype in this effect, we used serum protein electrophoresis to quantitate monoclonal and polyclonal immunoglobulins in patients and we used serum immunofixation electrophoresis to determine their M-protein isotype. When divided into populations of 30 patients with IgG M-proteins (mean 2.5 g/dl) and 19 patients with IgM or IgA M-proteins (mean 2.6 g/dl), the mean polyclonal immunoglobulin level was significantly lower in the IgG M-protein population (0.4 g/dl) than the IgM/IgA population (0.8 g/dl). Patients with IgG M-proteins also had significantly lower polyclonal immunoglobulin levels when compared separately with the patients with either IgA or IgM paraproteins. Since the polyclonal immunoglobulin fraction is comprised mostly of IgG, these results give the first direct indication that IgG M-proteins have a greater suppressive effect on polyclonal IgG levels than do M-proteins of other isotypes. These findings suggest that an isotype-specific feedback mechanism could be involved in the normal regulation of serum IgG levels.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11508831

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  6 in total

1.  Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma.

Authors:  E Kastritis; F Zagouri; A Symeonidis; M Roussou; A Sioni; A Pouli; S Delimpasi; E Katodritou; E Michalis; M Michael; E Hatzimichael; A Vassou; P Repousis; A Christophoridou; Z Kartasis; E Stefanoudaki; C Megalakaki; S Giannouli; M-C Kyrtsonis; K Konstantopoulos; M Spyroupoulou-Vlachou; E Terpos; M A Dimopoulos
Journal:  Leukemia       Date:  2014-03-18       Impact factor: 11.528

2.  Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease.

Authors:  Ignacio Isola; David F Moreno; Esther Moga; Mari-Pau Mena; Natalia Tovar; Luis Gerardo Rodríguez-Lobato; Aina Oliver-Caldés; M Carmen Salgado; Fara Brasó-Maristany; Jordi Yagüe; M Teresa Cibeira; Aleix Prat; Laura Rosiñol; Joan Bladé; Carlos Fernández de Larrea
Journal:  Ann Hematol       Date:  2021-08-31       Impact factor: 3.673

3.  Combined immune score of lymphocyte to monocyte ratio and immunoglobulin levels predicts treatment-free survival of multiple myeloma patients after autologous stem cell transplant.

Authors:  Karen Sweiss; Jonathan Lee; Nadim Mahmud; Gregory S Calip; Youngmin Park; Dolores Mahmud; Damiano Rondelli; Pritesh R Patel
Journal:  Bone Marrow Transplant       Date:  2019-09-16       Impact factor: 5.483

4.  Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials.

Authors:  Jennifer L J Heaney; John P Campbell; Gulnaz Iqbal; David Cairns; Alex Richter; J Anthony Child; Walter Gregory; Graham Jackson; Martin Kaiser; Roger Owen; Faith Davies; Gareth Morgan; Janet Dunn; Mark T Drayson
Journal:  Leukemia       Date:  2018-06-20       Impact factor: 11.528

5.  Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma.

Authors:  Heinz Ludwig; Dejan Milosavljevic; Oscar Berlanga; Niklas Zojer; Wolfgang Hübl; Veronique Fritz; Stephen Harding
Journal:  Am J Hematol       Date:  2016-03       Impact factor: 10.047

6.  Active multiple myeloma suppresses and typically eliminates coexisting MGUS.

Authors:  John P Campbell; Jennifer L J Heaney; Sankalp Pandya; Zaheer Afzal; Martin Kaiser; Roger Owen; J Anthony Child; Walter Gregory; Gareth J Morgan; Graham H Jackson; Chris M Bunce; Mark T Drayson
Journal:  Br J Cancer       Date:  2017-07-20       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.